References
- American College of Obstetricians and Gynecologists, Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in pregnancy. Obstet Gynecol. 2013;122:1122–1131.
- Steegers EA, von Dadelszen P, Duvekot JJ, et al. Pre-eclampsia. Lancet. 2010;376:631–644.
- Lowe SA, Brown MA, Dekker GA, et al. Guidelines for the management of hypertensive disorders of pregnancy 2008. Aust NZ J Obstet Gynaecol. 2009;49:242–246.
- Hutcheon JA, Lisonkova S, Joseph KS. Epidemiology of pre-eclampsia and the other hypertensive disorders of pregnancy. Best Pract Res Clin Obstet Gynaecol. 2011;25:391–403.
- Page EW. On the pathogenesis of pre-eclampsia and eclampsia. J Obstet Gynaecol Br Commonw. 1972;79:883–894.
- Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet. 2005;365:785–799.
- Chaiworapongsa T, Chaemsaithong P, Yeo L, et al. Pre-eclampsia part 1: current understanding of its pathophysiology. Nat Rev Nephrol. 2014;10:466–480.
- Viollet B, Athea Y, Mounier R, et al. AMPK: lessons from transgenic and knockout animals. Front Biosci (Landmark Ed). 2009;14:19–44.
- Steinberg GR, Kemp BE. AMPK in health and disease. Physiol Rev. 2009;89:1025–1078.
- Carey EA, Albers RE, Doliboa SR, et al. AMPK knockdown in placental trophoblast cells results in altered morphology and function. Stem Cells Dev. 2014;23:2921–2930.
- Waker CA, Albers RE, Pye RL, et al. AMPK knockdown in placental labyrinthine progenitor cells results in restriction of critical energy resources and terminal differentiation failure. Stem Cells Dev. 2017;26:808–817.
- Young BC, Levine RJ, Karumanchi SA. Pathogenesis of preeclampsia. Annu Rev Pathol. 2010;5:173–192.
- Abd El-Latif M, Azzam H, Othman M, et al. Assessment of annexin A5 and annexin A2 levels as biomarkers for pre-eclampsia: a pilot study. Pregnancy Hypertens. 2017;8:65–69.
- Chaiworapongsa T, Chaemsaithong P, Korzeniewski SJ, et al. Pre-eclampsia part 2: prediction, prevention and management. Nat Rev Nephrol. 2014;10:531–540.
- Mutter WP, Karumanchi SA. Molecular mechanisms of preeclampsia. Microvasc Res. 2008;75:1–8.
- Skeffington KL, Higgins JS, Mahmoud AD, et al. Hypoxia, AMPK activation and uterine artery vasoreactivity. J Physiol. 2016;594:1357–1369.
- Banek CT, Bauer AJ, Needham KM, et al. AICAR administration ameliorates hypertension and angiogenic imbalance in a model of preeclampsia in the rat. Am J Physiol Heart Circ Physiol. 2013;304:H1159–H1165.
- Malshe AK, Sibai BM. Angiogenic and antiangiogenic markers for prediction and risk classification of preeclampsia. Clin Obstet Gynaecol. 2017;60:134–140.
- Garcia-Tizon Larroca S, Tayyar A, Poon LC, et al. Competing risks model in screening for preeclampsia by biophysical and biochemical markers at 30–33 weeks’ gestation. Fetal Diagn Ther. 2014;36:9–17.
- Tayyar A, Garcia-Tizon Larroca S, Poon LC, et al. Competing risk model in screening for preeclampsia by mean arterial pressure and uterine artery pulsatility index at 30–33 weeks’ gestation. Fetal Diagn Ther. 2014;36:18–27.
- Jansson T, Powell TL. Role of placental nutrient sensing in developmental programming. Clin Obstet Gynaecol. 2013;56:591–601.
- Roos S, Powell TL, Jansson T. Placental mTOR links maternal nutrient availability to fetal growth. Biochem Soc Trans. 2009;37:295–298.
- Rosario FJ, Kanai Y, Powell TL, et al. Mammalian target of rapamycin signalling modulates amino acid uptake by regulating transporter cell surface abundance in primary human trophoblast cells. J Physiol. 2013;591:609–625.
- Kaufman MR, Brown TL. AMPK and placental progenitor cells. EXS. 2016;107:73–79.
- Romero R, Erez O, Hüttemann M, et al. Metformin, the aspirin of the 21st century: its role in gestational diabetes mellitus, prevention of preeclampsia and cancer, and the promotion of longevity. Am J Obstet Gynecol. 2017;217:282–302.